Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velzatinib Pharmacokinetics with Omeprazole or Cyclosporine in Healthy Participants
NCT07862114Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, open-label trial of velzatinib in gastrointestinal neoplasm (3 arms), sponsored by GSK. Primary endpoints: Maximum observed plasma concentration up to 72 hours and Area under the plasma concentration-time curve from time zero to 72 hours post-dose. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
velzatinib
03
Conditions
gastrointestinal neoplasm
Beyond the preview
Go deeper on NCT07862114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862114.